Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients
Clinical trial NCT04440436 · RECRUITING
Trial details
- NCT number
- NCT04440436
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-04
- Primary completion
- 2022-06-04
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.